The 64th ASH annual meeting and exposition took place on December 10-13, 2022 in New Orleans. The program at glance is available here. This year’s event was primarily an in-person event with virtual broadcasts available. Like last year, APLUSA exhibited in person with a physical booth. With this social media analysis, we will be assessing the impact of the conference online:
From the view of HCPs:
From the view of pharma companies:
The scope of the analysis is focused on mentions coming worldwide.*
*#ash22 OR #ash2022 OR #ASHTrainee OR #ASHkudos OR #ASHRunWalk OR #ASHaiku
There was a 16% increase in HCPs mentions when compared to last year. As usual, the peak of conversations happened during the conference representing 72% of mentions recorded during the listening period.
Most liked post, by the influential Vincent Rajkumar M.D., was a summary of the latest developments in the treatment of cancer as seen during the conference.
Most retweeted: Hematologist Ajay Major shared results from the NEUTRODIET trial with important implications on QoL for patients.
Most replied to: a post from an upcoming HCP receiving recognition during the conference, elicited engagement by way of congratulatory messages from fellow healthcare professionals.
The top hashtag was #mmsm (multiple myeloma social media).
Also of note, the use of the hashtags #imfash22 signifying the international Myeloma Foundation members’ attendance at the congress.
The official hashtag #ash22 was the most used one with the variation #ash2022 in second place. Note the use of specific hashtags such as #ashkudos and #ashtrainee corresponding with events organized by ASH during the conference.
Multiple myeloma, acute myeloid leukemia, and diffuse large B-cell lymphoma dominated online discussions.
Encouraging results from trials (iStopMM, GEM-CESAR and ASCENT) focusing on multiple myeloma precursors SMM and MGUs were put forth.
Apart from this, the spotlight was put on bispecific antibodies with talquetamab, elranatamab and cevostamab generating interest (see focus later in this document).
The iStopMM trial (Iceland Screen, Treats, or Prevents Multiple Myeloma) is described as the largest scientific study conducted in Iceland. Updates from this trial generated interest and enthusiasm from HCPs who deemed them practice-changing. The abstract “Predicting the Need for Upfront Bone Marrow” particularly stood out.
Non-BCMA targeted bispecifics are highlighted, giving yet another set of potential tools to combat multiple myeloma.
While impactful developments around CAR-T therapies were overall sparse, results from the FasTCAR and KarMMa studies stood out.
There were a total of 267 mentions during the listening period, chiefly down from 421 mentions last year.
Volume of mentions overtime ASH 2022: pharma companies
* "Reach" is a number assigned to a piece of content that is designed to estimate how many different individuals are likely to have seen that content, by taking into account metrics such as retweets, replies, followers of retweeters, and followers of the author.
** "Impressions" is a metric that only applies to Twitter and is a measure of the potential number of times a tweet may have been seen. "Total impressions" is the sum of the followers of the tweet author and the followers of any retweeting authors.
Janssen tops companies in volume of mentions. Incyte shows strong performance in terms of engagement.
Top 10 pharmaceutical companies by volume
Pfizer was the top pharmaceutical company in terms of impact.
Despite a more contained social media presence during ASH2022, Incyte benefited from significantly more engagement on their published content. This engagement was mostly fuelled by the announcement of Incyte’s INCA033989, a new anti-mutant calreticulin (CALR)-targeted monoclonal antibody, for potential treatment in myelofibrosis and essential thrombocythemia.